129 related articles for article (PubMed ID: 9579876)
1. Antibody-directed superantigen-mediated T-cell killing of myeloid leukaemic cell line cells.
Gidlöf C; Carlson B; Dohlsten M; Tötterman TH
Eur J Haematol; 1998 Apr; 60(4):233-9. PubMed ID: 9579876
[TBL] [Abstract][Full Text] [Related]
2. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
[TBL] [Abstract][Full Text] [Related]
3. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
[TBL] [Abstract][Full Text] [Related]
4. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
[TBL] [Abstract][Full Text] [Related]
5. Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells.
Riesbeck K; Billström A; Tordsson J; Brodin T; Kristensson K; Dohlsten M
Clin Diagn Lab Immunol; 1998 Sep; 5(5):675-82. PubMed ID: 9729535
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells.
Ragnarsson L; Strömberg T; Wijdenes J; Tötterman TH; Weigelt C
Cancer Immunol Immunother; 2001 Sep; 50(7):382-90. PubMed ID: 11676398
[TBL] [Abstract][Full Text] [Related]
7. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.
Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M
Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.
Dohlsten M; Hedlund G; Akerblom E; Lando PA; Kalland T
Proc Natl Acad Sci U S A; 1991 Oct; 88(20):9287-91. PubMed ID: 1924393
[TBL] [Abstract][Full Text] [Related]
9. Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells.
Holzer U; Bethge W; Krull F; Ihle J; Handgretinger R; Reisfeld RA; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Immunol Immunother; 1995 Aug; 41(2):129-36. PubMed ID: 7656271
[TBL] [Abstract][Full Text] [Related]
10. Superantigen-mediated cellular cytotoxicity is dependent on antigen expression, but independent of the P-glycoprotein multidrug resistance phenotype.
Zehrer C; Beck J; Gekeler V; Ihle J; Holzer U; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Br J Haematol; 1996 Dec; 95(3):452-6. PubMed ID: 8943883
[TBL] [Abstract][Full Text] [Related]
11. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones.
Firat H; Favier R; Adam M; Leverger G; Landman-Parker J; Cayre Y; Douay L
Leuk Lymphoma; 2001 Aug; 42(4):675-82. PubMed ID: 11697497
[TBL] [Abstract][Full Text] [Related]
12. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones.
Firat H; Favier R; Adam M; Leverger G; Landman-Parker J; Cayre Y; Douay L
Leuk Lymphoma; 2001 Jun; 42(1-2):75-82. PubMed ID: 11699224
[TBL] [Abstract][Full Text] [Related]
13. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
Chen J; Zhou JH; Ball ED
Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
[TBL] [Abstract][Full Text] [Related]
14. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD
Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000
[TBL] [Abstract][Full Text] [Related]
15. Superantigen-induced lysis of melanoma cells.
Krull F; Holzer U; Ihle J; Bethge W; Fierlbeck G; Kalland T; Dohlsten M; Niethammer D; Dannecker GE
Melanoma Res; 1997 Jun; 7(3):214-22. PubMed ID: 9195560
[TBL] [Abstract][Full Text] [Related]
16. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review.
Frankel AE; Sievers EL; Scheinberg DA
Cancer Biother Radiopharm; 2000 Oct; 15(5):459-76. PubMed ID: 11155818
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of lysis of leukaemia cells by a bispecific antibody to CD33 and CD16 (Fc gamma RIII) expressed by human natural killer (NK) cells.
Silla LM; Chen J; Zhong RK; Whiteside TL; Ball ED
Br J Haematol; 1995 Apr; 89(4):712-8. PubMed ID: 7772507
[TBL] [Abstract][Full Text] [Related]
18. Surface marker expression in acute myeloid leukaemia at first relapse.
Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D
Br J Haematol; 1992 May; 81(1):40-4. PubMed ID: 1381608
[TBL] [Abstract][Full Text] [Related]
19. Targeted superantigens for immunotherapy of haematopoietic tumours.
Tötterman TH; Gidlöf C; Ragnarsson L; Högbom E; Lindeberg M; von der Lehr N; Einarsson A; Soegaard M; Kristensson K; Kalland T; Dohlsten M
Vox Sang; 1998; 74 Suppl 2():483-7. PubMed ID: 9704486
[TBL] [Abstract][Full Text] [Related]
20. Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.
Sutherland MK; Yu C; Lewis TS; Miyamoto JB; Morris-Tilden CA; Jonas M; Sutherland J; Nesterova A; Gerber HP; Sievers EL; Grewal IS; Law CL
MAbs; 2009; 1(5):481-90. PubMed ID: 20065652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
